Publications
Publications
  • November 2017
  • Case
  • HBS Case Collection

BeiGene

By: Willy Shih and Jimmy Zhang
  • Format:Print
  • | Language:English
  • | Pages:12
ShareBar

Abstract

BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window of opportunity to develop drug candidates toward known targets with known mechanisms of actions that would allow it to become first-in-class in China. But how well would the company's strategy hold up to the 2017 regulatory reforms?

Keywords

Biotechnology; Pharmaceutical Company; Pharmaceuticals; China; Regulatory Environment; Business Strategy; Business Startups; Innovation Strategy; Situation or Environment; Pharmaceutical Industry; China

Citation

Shih, Willy, and Jimmy Zhang. "BeiGene." Harvard Business School Case 618-033, November 2017.

About The Author

Willy C. Shih

Technology and Operations Management
More Publications

Related Work